The psychosis spectrum in Parkinson disease

[1]  A. Lees,et al.  Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. , 2016, Parkinsonism & related disorders.

[2]  P. Pal,et al.  Genetic substrates of psychosis in patients with Parkinson's disease: A critical review , 2016, Journal of the Neurological Sciences.

[3]  D. Weintraub,et al.  Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. , 2016, JAMA neurology.

[4]  J. Obeso,et al.  Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment , 2016, Human brain mapping.

[5]  J. Friedman.  Editorial on: Pagonabarraga J, Martinez‐Hora S, Fernandez de Bobadilla R et al. Minor hallucinations occur in drug‐naïve Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; Available from: DOI: 10.1002/mds.26432 , 2016, Movement disorders : official journal of the Movement Disorder Society.

[6]  J. Kulisevsky,et al.  Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase , 2016, Movement disorders : official journal of the Movement Disorder Society.

[7]  P. Pal,et al.  Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: A review. , 2016, Parkinsonism & related disorders.

[8]  J. O'Brien,et al.  The relationship between hallucinations and FDG-PET in dementia with Lewy bodies , 2016, Brain Imaging and Behavior.

[9]  D. Chan,et al.  Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson’s Disease Patients , 2015, Front. Neurol..

[10]  Tomoko Oeda,et al.  Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease , 2015, Neurobiology of Aging.

[11]  O. Rascol,et al.  Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. , 2015, Journal of the American Medical Directors Association.

[12]  P. Pal,et al.  Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: A critical review. , 2015, Parkinsonism & related disorders.

[13]  J. Barnes,et al.  Phenomenology of Visual Hallucinations and Their Relationship to Cognitive Profile in Parkinson’s Disease Patients , 2015 .

[14]  P. Svenningsson,et al.  EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[15]  T. Kawada.  Predictors of dementia in Parkinson disease: A prospective cohort study , 2015, Neurology.

[16]  D. Ffytche,et al.  On visual hallucinations and cortical networks: a trans-diagnostic review , 2015, Journal of Neurology.

[17]  E. Chung,et al.  A comparison of Montreal Cognitive Assessment between patients with visual hallucinations and without visual hallucinations in Parkinson's disease , 2015, Clinical Neurology and Neurosurgery.

[18]  Shu-Leong Ho,et al.  Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations. , 2015, Parkinsonism & related disorders.

[19]  S. Tufik,et al.  Risk factors for visual hallucinations in patients with Parkinson’s disease , 2015, Neurological research.

[20]  A Smith,et al.  Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus , 2015, Molecular Psychiatry.

[21]  J. Shine,et al.  Imagine that: elevated sensory strength of mental imagery in individuals with Parkinson's disease and visual hallucinations , 2015, Proceedings of the Royal Society B: Biological Sciences.

[22]  Y Wang,et al.  Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci , 2014, Molecular Psychiatry.

[23]  Kwangsik Nho,et al.  Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults. , 2015, Journal of Alzheimer's disease : JAD.

[24]  W. McDonald,et al.  Cognitive correlates of hallucinations and delusions in Parkinson's disease , 2014, Journal of the Neurological Sciences.

[25]  G. Halliday,et al.  Visual hallucinations in Parkinson's disease: Theoretical models , 2014, Movement disorders : official journal of the Movement Disorder Society.

[26]  Kara M. Smith,et al.  Course of psychiatric symptoms and global cognition in early Parkinson disease , 2014, Neurology.

[27]  H. Shill,et al.  Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. , 2014, Parkinsonism & related disorders.

[28]  J. Suckling,et al.  The default mode network is disrupted in parkinson's disease with visual hallucinations , 2014, Human brain mapping.

[29]  S. Tufik,et al.  Structural brain abnormalities in patients with Parkinson’s disease with visual hallucinations: A comparative voxel-based analysis , 2014, Brain and Cognition.

[30]  E. Londos,et al.  Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. , 2014, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[31]  M. Hutz,et al.  Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients , 2013, The Pharmacogenomics Journal.

[32]  M. Frank,et al.  Cognitive correlates of psychosis in patients with Parkinson's disease , 2014, Cognitive neuropsychiatry.

[33]  Lilah M. Besser,et al.  Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. , 2014, Parkinsonism & related disorders.

[34]  G. Halliday,et al.  Tricks of the mind: Visual hallucinations as disorders of attention , 2014, Progress in Neurobiology.

[35]  G. Halliday,et al.  The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease , 2014, Human brain mapping.

[36]  Christine Schiltz,et al.  Are patients with Parkinson’s disease blind to blindsight? , 2014, Brain : a journal of neurology.

[37]  P. Murray,et al.  Psychosis in Alzheimer’s Disease , 2014, Biological Psychiatry.

[38]  N. Hattori,et al.  Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease , 2014, Neurobiology of Aging.

[39]  E. Mori,et al.  Hallucinators find meaning in noises: Pareidolic illusions in dementia with Lewy bodies , 2014, Neuropsychologia.

[40]  Alan J. Thomas,et al.  Visual complaints and visual hallucinations in Parkinson's disease. , 2014, Parkinsonism & related disorders.

[41]  J. Kulisevsky,et al.  Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. , 2014, Parkinsonism & related disorders.

[42]  G. Stebbins,et al.  Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. , 2014, Brain : a journal of neurology.

[43]  J. Cummings,et al.  Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial , 2014, The Lancet.

[44]  Han-Joon Kim,et al.  Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's Disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[45]  G. Stebbins,et al.  I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging , 2014, Movement disorders : official journal of the Movement Disorder Society.

[46]  K. Ray Chaudhuri,et al.  Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease. , 2013, Parkinsonism & related disorders.

[47]  G. Sobue,et al.  Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination , 2013, Movement Disorders.

[48]  Kunhua Wu,et al.  Why psychosis is frequently associated with Parkinson's disease? , 2013, Neural regeneration research.

[49]  Jae-Hong Lee,et al.  Visual Hallucinations and Cognitive Impairment in Parkinson's Disease , 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[50]  M. Moscovich,et al.  Delusional misidentification syndrome and other unusual delusions in advanced Parkinson's disease. , 2013, Parkinsonism & related disorders.

[51]  M. Hutz,et al.  Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. , 2013, The international journal of neuropsychopharmacology.

[52]  H. Putter,et al.  Risk factors for hallucinations in Parkinson's disease: Results from a large prospective cohort study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[53]  S. Landau,et al.  Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4‐year study , 2013, International journal of geriatric psychiatry.

[54]  M. Stamelou,et al.  Dopamine agonists and delusional jealousy in Parkinson's disease: A cross‐sectional prevalence study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[55]  J. Cummings,et al.  Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. , 2013, Parkinsonism & related disorders.

[56]  M. Ban,et al.  Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. , 2013, Brain : a journal of neurology.

[57]  J. Friedman,et al.  Parkinson Disease Psychosis: Update , 2013, Behavioural neurology.

[58]  I. Bodis-Wollner.  Foveal vision is impaired in Parkinson's disease. , 2013, Parkinsonism & related disorders.

[59]  John-Paul Taylor,et al.  Visual Hallucinations in PD and Lewy Body Dementias: Old and New Hypotheses , 2013, Behavioural neurology.

[60]  Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson's disease , 2012, Journal of the Neurological Sciences.

[61]  E. Londos,et al.  No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias , 2012, Neuroscience Letters.

[62]  C. Tanner,et al.  Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[63]  Y. Sohn,et al.  Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[64]  H. Botha,et al.  Attention and visual dysfunction in Parkinson's disease. , 2012, Parkinsonism & related disorders.

[65]  L. Hazrati,et al.  Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[66]  G. H. Halliday,et al.  Investigating visual misperceptions in Parkinson's disease: A novel behavioral paradigm , 2012, Movement disorders : official journal of the Movement Disorder Society.

[67]  P. Rabins,et al.  Prevalence of psychotic symptoms in a community-based Parkinson disease sample. , 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[68]  E. Tolosa,et al.  Cerebral basis of visual hallucinations in Parkinson's disease: Structural and functional MRI studies , 2011, Journal of the Neurological Sciences.

[69]  U. Mosimann,et al.  Visual symptoms in Parkinson's disease and Parkinson's disease dementia , 2011, Movement disorders : official journal of the Movement Disorder Society.

[70]  David R Williams,et al.  Testing an aetiological model of visual hallucinations in Parkinson's disease. , 2011, Brain : a journal of neurology.

[71]  G. Halliday,et al.  Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks? , 2011, Movement disorders : official journal of the Movement Disorder Society.

[72]  S. Factor,et al.  Disease‐related and genetic correlates of psychotic symptoms in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[73]  G. Stebbins,et al.  Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years , 2011, Movement disorders : official journal of the Movement Disorder Society.

[74]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[75]  N. Hattori,et al.  Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[76]  R. Marconi,et al.  Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[77]  S. Leurgans,et al.  Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations , 2011, Movement disorders : official journal of the Movement Disorder Society.

[78]  H. Berendse,et al.  The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study , 2011, Journal of Neurology.

[79]  G. Fénelon,et al.  Feeling of presence in Parkinson's disease , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[80]  K. Sethi,et al.  Fast Facts: Parkinson's Disease , 2011 .

[81]  J. Barnes,et al.  Visual Memory Errors in Parkinson's Disease Patient With Visual Hallucinations , 2011, The International journal of neuroscience.

[82]  T. van Laar,et al.  Chapter 5 Regional cortical grey matter loss in Parkinson ’ s disease without dementia is independent from visual hallucinations , 2011 .

[83]  G. Sobue,et al.  Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease. , 2011, Parkinsonism & related disorders.

[84]  J. Kulisevsky,et al.  Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[85]  J. Friedman.  Parkinson's disease psychosis 2010: a review article. , 2010, Parkinsonism & related disorders.

[86]  G. Stebbins,et al.  A 12-year population-based study of psychosis in Parkinson disease. , 2010, Archives of neurology.

[87]  H. Katzen,et al.  Multi-Modal Hallucinations and Cognitive Function in Parkinson’s Disease , 2010, Dementia and Geriatric Cognitive Disorders.

[88]  Y. Okubo,et al.  Marked Improvement of Psychotic Symptoms After Electroconvulsive Therapy in Parkinson Disease , 2010, The journal of ECT.

[89]  T. van Laar,et al.  Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. , 2010, Parkinsonism & related disorders.

[90]  G. Fénelon,et al.  Four novel mutations in the GCH1 gene of Chinese patients with dopa‐responsive dystonia , 2010, Movement disorders : official journal of the Movement Disorder Society.

[91]  Carles Falcon,et al.  Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia , 2010, Movement disorders : official journal of the Movement Disorder Society.

[92]  S. Houle,et al.  Serotonin 2A receptors and visual hallucinations in Parkinson disease. , 2010, Archives of neurology.

[93]  J. Friedman,et al.  Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis , 2010, Neuropsychopharmacology.

[94]  Guido Alves,et al.  Epidemiology of psychosis in Parkinson's disease , 2010, Journal of the Neurological Sciences.

[95]  Masahiko Suzuki,et al.  Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies , 2010, Movement disorders : official journal of the Movement Disorder Society.

[96]  C. Goetz.  New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[97]  T. van Laar,et al.  Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. , 2010, Parkinsonism & related disorders.

[98]  E. Tolosa,et al.  Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[99]  J. Rabey.  Hallucinations and psychosis in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[100]  S. Anderson,et al.  Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort , 2009, Neurology.

[101]  F. Cornelissen,et al.  Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. , 2009, Brain : a journal of neurology.

[102]  W. Brouwer,et al.  The Effects of Apomorphine on Visual Perception in Patients With Parkinson Disease and Visual Hallucinations: A Pilot Study , 2009, Clinical neuropharmacology.

[103]  Raffaele Dubbioso,et al.  Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. , 2009, Brain : a journal of neurology.

[104]  G. Muscettola,et al.  HOMER1 Promoter Analysis in Parkinson’s Disease: Association Study with Psychotic Symptoms , 2009, Neuropsychobiology.

[105]  R. Walker,et al.  Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. , 2009, Parkinsonism & related disorders.

[106]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[107]  E. Londos,et al.  Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial , 2009, The Lancet Neurology.

[108]  D. Aarsland,et al.  The association between motor subtypes and psychopathology in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[109]  G. Stebbins,et al.  Hallucinations in Parkinson disease , 2009, Nature Reviews Neurology.

[110]  A. David,et al.  A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease , 2009, Neuropsychiatric disease and treatment.

[111]  L. Moran,et al.  Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[112]  D. Ffytche.  Visual hallucinations in eye disease , 2009, Current opinion in neurology.

[113]  G. Meco,et al.  Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of l-dopa-induced adverse effects , 2009, Journal of the Neurological Sciences.

[114]  Carlos Falcón,et al.  Brain response to complex visual stimuli in Parkinson's patients with hallucinations: A functional magnetic resonance imaging study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[115]  Klaus Leonard Leenders,et al.  Visual object recognition and attention in Parkinson's disease patients with visual hallucinations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[116]  E. Tolosa,et al.  Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia , 2008, Journal of Neurology.

[117]  Dominic H. ffytche,et al.  The hodology of hallucinations , 2008, Cortex.

[118]  I. McKeith,et al.  A semi‐structured interview to assess visual hallucinations in older people , 2008, International journal of geriatric psychiatry.

[119]  H. Katzen,et al.  A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease , 2008, BMC neurology.

[120]  D. Ffytche,et al.  Decomposing the neural correlates of antisaccade eye movements using event-related FMRI. , 2008, Cerebral cortex.

[121]  K. Nakashima,et al.  Executive dysfunction in non‐demented Parkinson’s disease patients with hallucinations , 2008, Acta neurologica Scandinavica.

[122]  W. Poewe,et al.  Scales to assess psychosis in Parkinson's disease: Critique and recommendations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[123]  G. Fénelon.  Psychosis in Parkinson's Disease: Phenomenology, Frequency, Risk Factors, and Current Understanding of Pathophysiologic Mechanisms , 2008, CNS Spectrums.

[124]  Jaime Kulisevsky,et al.  A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia , 2008, Movement disorders : official journal of the Movement Disorder Society.

[125]  Y. Furiya,et al.  Increased temporal blood flow associated with visual hallucinations in Parkinson's disease with dementia , 2008, Movement disorders : official journal of the Movement Disorder Society.

[126]  A. Quattrone,et al.  Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy , 2008, Movement disorders : official journal of the Movement Disorder Society.

[127]  J. Barnes,et al.  Executive functions are impaired in patients with Parkinson’s disease with visual hallucinations , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[128]  R C Grace,et al.  A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. , 2008, Parkinsonism & related disorders.

[129]  L. Hanoglu,et al.  Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease , 2007, Clinical Neurology and Neurosurgery.

[130]  L. Hanoglu,et al.  Cognitive impairment patterns in Parkinson’s disease with visual hallucinations , 2007, Journal of Clinical Neuroscience.

[131]  Mitsuyoshi Urashima,et al.  Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations , 2007, Movement disorders : official journal of the Movement Disorder Society.

[132]  L. Murri,et al.  Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes , 2007, Neuroscience Letters.

[133]  E. Tolosa,et al.  Cerebral atrophy in Parkinson's disease patients with visual hallucinations , 2007, European journal of neurology.

[134]  A. Ceballos-Baumann,et al.  Metabolic alterations in patients with Parkinson disease and visual hallucinations. , 2007, Archives of neurology.

[135]  G. Ebersbach,et al.  Selective diplopia in Parkinson's disease: A special subtype of visual hallucination? , 2007, Movement disorders : official journal of the Movement Disorder Society.

[136]  K. Gwinn‐Hardy,et al.  Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group , 2007, Movement disorders : official journal of the Movement Disorder Society.

[137]  Dominic H. ffytche,et al.  Visual hallucinatory syndromes: past, present, and future , 2007, Dialogues in clinical neuroscience.

[138]  L. Thal,et al.  Quetiapine for agitation or psychosis in patients with dementia and parkinsonism , 2007, Neurology.

[139]  E. Tolosa,et al.  Cognitive Changes in Parkinson’s Disease Patients with Visual Hallucinations , 2007, Dementia and Geriatric Cognitive Disorders.

[140]  M. Farrer,et al.  Phenotypic associations of tau and ApoE in Parkinson's disease , 2007, Neuroscience Letters.

[141]  H. Harn,et al.  Genetic polymorphism of the angiotensin converting enzyme and l-dopa-induced adverse effects in Parkinson's disease , 2007, Journal of the Neurological Sciences.

[142]  I. McKeith,et al.  Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[143]  G. Albani,et al.  Visual hallucinations in Parkinson's disease: Clues to separate origins , 2006, Journal of the Neurological Sciences.

[144]  Carme Junqué,et al.  Neuropsychological deficits in Parkinson's disease patients with visual hallucinations , 2006, Movement disorders : official journal of the Movement Disorder Society.

[145]  G. Wooten,et al.  Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. , 2006, The Journal of neuropsychiatry and clinical neurosciences.

[146]  Deborah C Mash,et al.  Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. , 2006, Parkinsonism & related disorders.

[147]  S. Leurgans,et al.  The malignant course of "benign hallucinations" in Parkinson disease. , 2006, Archives of neurology.

[148]  A. Korczyn,et al.  Apolipoprotein ɛ4 advances appearance of psychosis in patients with Parkinson's disease , 2006 .

[149]  S. Papapetropoulos.  Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. , 2006, Clinical neuropharmacology.

[150]  H. Fukuyama,et al.  Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations , 2005, Neurology.

[151]  E. Perry,et al.  Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations , 2005, Behavioral and Brain Sciences.

[152]  W. Ondo,et al.  Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[153]  Luigi Trojano,et al.  Frontal dysfunction contributes to the genesis of hallucinations in non‐demented Parkinsonian patients , 2005, International Journal of Geriatric Psychiatry.

[154]  M. Oda,et al.  The Relation Between Visual Hallucinations and Visual Evoked Potential in Parkinson Disease , 2005, Clinical neuropharmacology.

[155]  G. Stebbins,et al.  Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model , 2005, Movement disorders : official journal of the Movement Disorder Society.

[156]  G. Glover,et al.  Altered cortical visual processing in PD with hallucinations , 2004, Neurology.

[157]  S. Leurgans,et al.  Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. , 2004, Archives of neurology.

[158]  Akinori Nakamura,et al.  Visual hallucination in Parkinson's disease with FDG PET , 2004, Movement disorders : official journal of the Movement Disorder Society.

[159]  A. Destée,et al.  Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[160]  Biao Chen,et al.  Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease , 2004, Neuroscience Letters.

[161]  G. Ebersbach.  An artist's view of drug‐induced hallucinosis , 2003, Movement disorders : official journal of the Movement Disorder Society.

[162]  A. Kupsch,et al.  l -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism , 2003, Neurology.

[163]  Jian Wang,et al.  Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. , 2003, Pharmacogenetics.

[164]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[165]  D. Aarsland,et al.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. , 2003, Archives of neurology.

[166]  G. Halliday,et al.  Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. , 2002, Brain : a journal of neurology.

[167]  J. Jankovic,et al.  Olanzapine treatment for dopaminergic‐induced hallucinations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[168]  J. Friedman,et al.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.

[169]  M. Onofrj,et al.  Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up , 2002, Neurological Sciences.

[170]  G. Halliday,et al.  Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. , 2002, Brain : a journal of neurology.

[171]  Satoshi Minoshima,et al.  Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation , 2001, Annals of neurology.

[172]  J D Fenwick,et al.  Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD , 2001, Neurology.

[173]  S. Leurgans,et al.  Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. , 2001, Archives of neurology.

[174]  S. Leucht.  Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. , 2001, Neurology.

[175]  D. Ffytche,et al.  Visual hallucinatory syndromes and the anatomy of the visual brain. , 2000, Brain : a journal of neurology.

[176]  D. Paleacu,et al.  Re: The apolipoprotein E epsilon4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. , 2000, Clinical neuropharmacology.

[177]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[178]  K. Aitchison,et al.  Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. , 2000, Pharmacogenetics.

[179]  S. Harada,et al.  Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease , 1999, Clinical genetics.

[180]  E. Perry,et al.  Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. , 1999, The American journal of psychiatry.

[181]  E. Kraft,et al.  Visual hallucinations, white matter lesions and disease severity in Parkinson's disease , 1999, Acta neurologica Scandinavica.

[182]  S. Yamaguchi,et al.  Medication-induced hallucination and cerebral blood flow in Parkinson’s disease , 1999, Journal of Neurology.

[183]  R. de la Fuente-Fernández,et al.  The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. , 1999, Clinical neuropharmacology.

[184]  Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. , 1999, The New England journal of medicine.

[185]  P. Odin,et al.  Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up , 1998, Journal of neurology, neurosurgery, and psychiatry.

[186]  D. Paleacu,et al.  Apolipoprotein E and Parkinson's disease , 1998, Annals of neurology.

[187]  A. Korczyn,et al.  Auditory hallucinations in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[188]  G. Stebbins,et al.  Intravenous levodopa in hallucinating Parkinson's disease patients , 1998, Neurology.

[189]  R. Remick,et al.  Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis , 1990, Neurology.